Vaccines Market Size, Share, Growth & Industry Analysis, By Technology (Live Attenuated Vaccines, Conjugate Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other Vaccines), By Disease Indication (Pneumococcal Disease, Influenza, Human Papillomavirus, Meningococcal Disease, Rotavirus, Varicella, Diphtheria, Pertussis and Tetanus {DPT}, Polio, Hepatitis, Measles Mumps and Rubella {MMR}, Other Indicators), and Regional Analysis, 2024-2031

1 INTRODUCTION OF THE GLOBAL VACCINES MARKET
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Limitations
1.5 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 Data Collection
3.1.1 Secondary Sources
3.1.2 Primary Sources
3.1.3 Research Flow
3.2 Subject Matter Expert Advice
3.3 Quality Check
3.4 Final Review
3.5 Bottom-Up Approach
3.6 Top-down Approach

4 GLOBAL VACCINES MARKET OUTLOOK
4.1 Market Evolution
4.2 Overview
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.3.4 Challenges
4.4 Pricing Analysis
4.5 Porter’s Five Forces Analysis
4.6 Value Chain Analysis
4.7 Macroeconomic Analysis

5 IMPACT OF RUSSIA-UKRAINE WAR

6 GLOBAL VACCINES MARKET, BY TECHNOLOGY
6.1 Overview
6.2 Live Attenuated Vaccines
6.3 Conjugate Vaccines
6.4 Inactivated Vaccines
6.5 Toxoid Vaccines
6.6 Recombinant Vaccines
6.7 Other Vaccines

7 GLOBAL VACCINES MARKET, BY DISEASE INDICATION
7.1 Overview
7.2 Pneumococcal Disease
7.3 Influenza
7.4 Human Papillomavirus
7.5 Meningococcal Disease
7.6 Rotavirus
7.7 Varicella
7.8 Diphtheria
7.9 Pertussis and Tetanus {DPT}
7.10 Polio
7.11 Hepatitis
7.12 Measles Mumps and Rubella {MMR}
7.13 Other Indicators

8 GLOBAL VACCINES MARKET, BY GEOGRAPHY
8.1 Overview

9 NORTH AMERICA
9.1 U.S.
9.2 Canada
9.3 Mexico

10 EUROPE
10.1 Germany
10.2 UK
10.3 France
10.4 Italy
10.5 Spain
10.6 Russia
10.7 Rest of Europe

11 ASIA-PACIFIC
11.1 China
11.2 Japan
11.3 India
11.4 South Korea
11.5 Rest of Asia-Pacific

12 MIDDLE EAST & AFRICA
12.1 GCC
12.2 South Africa
12.3 North Africa
12.4 Rest of Middle East & Africa

13 LATIN AMERICA
13.1 Brazil
13.2 Argentina
13.3 Rest of South America

14 GLOBAL VACCINES MARKET COMPETITIVE LANDSCAPE
14.1 Overview
14.2 Key Developments
14.3 Key Strategic Developments
14.4 Company Market Ranking
14.5 Regional Footprint
14.6 Industry Footprint

15 COMPANY PROFILES
15.1 Pfizer Inc.
15.1.1 Key Facts
15.1.2 Financial Overview
15.1.3 Product Benchmarking
15.1.4 Recent Developments
15.1.5 Winning Imperatives
15.1.6 Current Focus & Strategies
15.1.7 Threat from competition
15.1.8 SWOT Analysis
15.2 Johnson & Johnson
15.2.1 Key Facts
15.2.2 Financial Overview
15.2.3 Product Benchmarking
15.2.4 Recent Developments
15.2.5 Winning Imperatives
15.2.6 Current Focus & Strategies
15.2.7 Threat from competition
15.2.8 SWOT Analysis
15.3 GlaxoSmithKline plc
15.3.1 Key Facts
15.3.2 Financial Overview
15.3.3 Product Benchmarking
15.3.4 Recent Developments
15.3.5 Winning Imperatives
15.3.6 Current Focus & Strategies
15.3.7 Threat from competition
15.3.8 SWOT Analysis
15.4 Sanofi
15.4.1 Key Facts
15.4.2 Financial Overview
15.4.3 Product Benchmarking
15.4.4 Recent Developments
15.4.5 Winning Imperatives
15.4.6 Current Focus & Strategies
15.4.7 Threat from competition
15.4.8 SWOT Analysis
15.5 Merck & Co., Inc.
15.5.1 Key Facts
15.5.2 Financial Overview
15.5.3 Product Benchmarking
15.5.4 Recent Developments
15.5.5 Winning Imperatives
15.5.6 Current Focus & Strategies
15.5.7 Threat from competition
15.5.8 SWOT Analysis
15.6 Novartis AG
15.6.1 Key Facts
15.6.2 Financial Overview
15.6.3 Product Benchmarking
15.6.4 Recent Developments
15.7 AstraZeneca plc
15.7.1 Key Facts
15.7.2 Financial Overview
15.7.3 Product Benchmarking
15.7.4 Recent Developments
15.8 Moderna, Inc.
15.8.1 Key Facts
15.8.2 Financial Overview
15.8.3 Product Benchmarking
15.8.4 Recent Developments
15.9 Sinovac Biotech Ltd.
15.9.1 Key Facts
15.9.2 Financial Overview
15.9.3 Product Benchmarking
15.9.4 Recent Developments
15.10 Bharat Biotech International Limited
15.10.1 Key Facts
15.10.2 Financial Overview
15.10.3 Product Benchmarking
15.10.4 Recent Developments

LIST OF TABLES

TABLE 1 Global Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 2 Global Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 3 Global Vaccines Market Revenue, By Geography, 2021 – 2031 (USD Million)
TABLE 4 North America Vaccines Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 5 North America Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 6 North America Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 7 US Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 8 US Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 9 Canada Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 10 Canada Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 11 Mexico Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 12 Mexico Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 13 Europe Vaccines Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 14 Europe Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 15 Europe Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 16 Germany Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 17 Germany Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 18 France Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 19 France Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 20 UK Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 21 UK Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 22 Spain Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 23 Spain Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 24 Italy Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 25 Italy Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 26 Russia Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 27 Russia Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 28 Rest of Europe Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 29 Rest of Europe Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 30 Asia-Pacific Vaccines Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 31 Asia-Pacific Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 32 Asia-Pacific Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 33 China Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 34 China Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 35 Japan Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 36 Japan Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 37 India Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 38 India Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 39 South Korea Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 40 South Korea Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 41 Rest of Asia-Pacific Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 42 Rest of Asia-Pacific Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 43 Middle East and Africa Vaccines Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 44 Middle East and Africa Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 45 Middle East and Africa Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 46 GCC Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 47 GCC Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 48 North Africa Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 49 North Africa Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 50 South Africa Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 51 South Africa Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 52 Rest of Middle East & Africa Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 53 Rest of Middle East & Africa Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 54 Latin America Vaccines Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 55 Latin America Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 56 Latin America Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 57 Brazil Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 58 Brazil Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 59 Argentina Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 60 Argentina Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
TABLE 61 Rest of Latin America Vaccines Market Revenue, By Technology, 2021 – 2031 (USD Million)
TABLE 62 Rest of Latin America Vaccines Market Revenue, By Disease Indication, 2021 – 2031 (USD Million)
Million)
TABLE 63 Company Market Ranking
TABLE 64 Regional Footprint
TABLE 65 Product Benchmarking
TABLE 66 Recent Developments
TABLE 67 Winning Imperatives

LIST OF FIGURES

FIG. 1 Market Segmentation
FIG. 2 Research Timeline
FIG. 3 Global Vaccines Market 2021-2031 (USD Million)
FIG. 4 Global Vaccines Market Geographical Analysis (CAGR %)
FIG. 5 Global Vaccines Absolute Market Opportunity (USD Million)
FIG. 6 Global Vaccines Market Attractiveness (USD Million)
FIG. 7 Global Vaccines Market, By Technology, 2021-2031 (USD Million)
FIG. 8 Global Vaccines Market, By Disease Indication, 2021-2031 (USD Million)
FIG. 9 Research Methodology
FIG. 10 Research Process
FIG. 11 Bottom-Up Approach
FIG. 12 Top-Bottom Approach
FIG. 13 Market Dynamics Overview
FIG. 14 Porter's Five Forces Analysis
FIG. 15 Value Chain Analysis
FIG. 16 Macroeconomic Analysis
FIG. 17 Global Vaccines Market Revenue Share, By Technology, 2021 and 2031 (%)
FIG. 18 Global Vaccines Market Revenue Share, By Disease Indication, 2021 and 2031 (%)
FIG. 19 Global Vaccines Market Revenue Share, By Geographic Regions, 2021 and 2031 (%)
FIG. 20 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 21 North America Vaccines Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 22 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 23 Europe Vaccines Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 24 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 25 Asia-Pacific Vaccines Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 26 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 27 Middle East & Africa Vaccines Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 28 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 29 Latin America Vaccines Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 30 Key Strategic Development
FIG. 31 Key Facts
FIG. 32 Financial Overview
FIG. 33 SWOT Analysis